Estuary Biotherapeutics
Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.
$93MSeries A
ParticipantGG
GV (Google Ventures)
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Jul 20, 2026
GV invests in technology and life-science companies, including AI applications, developer tools, cybersecurity, computing infrastructure and healthcare.
Its AI interests span the stack: new computing systems and inference infrastructure, tools for developers, software for professional workflows and applications in drug discovery and patient care. This gives both infrastructure founders and application builders a route to a specialist investment team.
GV developed the design sprint, a five-day process that takes a business question through problem definition, prototyping and customer testing. Its published sprint materials help teams test demand and product decisions before committing to a full launch.
- Rounds participated in
- 9
- Confirmed lead rounds
- 1 3 roles undisclosed
- New companies
- 8 First participation on record · 1 follow-on
- Funding in participating rounds
- $1.7B 9 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
9 in this selectionOMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
ParticipantArmadin
Armadin develops AI agents that test attack paths across enterprise systems and show defenders how connected weaknesses could be exploited.
$255.5MSeries B
ParticipantMetaview
Metaview provides AI agents and software for recruiters and hiring teams, from candidate sourcing and screening to interview notes and reporting.
$60MSeries C
ParticipantSnorkel AI
Snorkel AI helps enterprises build expert-curated training data and benchmarks for advanced AI models and agents.
$350MSeries E
ParticipantEncoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
LeadBlacksmith
Cloud infrastructure for validating and testing AI-generated code faster
$45MSeries B
Role not disclosedLifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedObsidian Security
Secures non-human identities and AI agents operating in third-party applications
$85MSeries D
Role not disclosed